1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Generation Income Properties said LC2, an affiliate of Loci Capital Partners, confirmed on September 24, 2026 that its preferred equity investment in GIP SPE, LLC has been fully redeemed for $4,160,217, funded mainly by net proceeds from a warrant exercise disclosed on September 21, 2026. The company said the redemption removes the preferred investment from its balance sheet, while its Nasdaq bid price compliance requirement remains outstanding.
LC2 confirmed full redemption on September 24, 2026 of the remaining preferred equity in GIP SPE, LLC.
Total remaining redemption payment and costs were $4,160,217, funded principally by net proceeds from the warrant exercise disclosed September 21, 2026.
The original $14.1 million preferred investment from LC2 was partial financing for the August 2023 purchase of properties from Modiv Inc.
The company must still maintain a closing bid price of at least $1.00 per share for Nasdaq compliance and says a reverse stock split is available if necessary.
GT Biopharma received notice from Nasdaq on September 22, 2026, that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company's common stock maintained a closing bid price above $1.00 for at least ten consecutive business days, which Nasdaq required. The regained compliance removes the risk of delisting that the company had faced under the earlier deadline of November 16, 2026.
Nasdaq notified GT Biopharma on September 22, 2026 that it regained compliance with the minimum bid price requirement.
The stock had closed below $1.00 for 30 consecutive business days, leading to a Nasdaq notice on November 20, 2025.
On May 20, 2026, Nasdaq granted an additional 180 calendar day compliance period, through November 16, 2026.
The company's common stock closed above $1.00 for at least ten consecutive business days to meet the standard.
Worthington Enterprises reported unaudited results for the first quarter of fiscal 2027, ended August 31, 2026: sales rose 13% to $344 million, and adjusted EPS was $0.82 versus $0.78 a year earlier, while gross margin fell to 26.4% from 27.1%. The company also granted CEO Joseph Hayek 150,000 performance shares and reported that three directors retired at its September 22, 2026 annual meeting.
Sales rose 13% to $344 million; adjusted EBITDA was $74 million versus $67 million a year earlier.
GAAP EPS was $0.87 versus $0.70; the quarter included a net $0.05 per share nonrecurring benefit and about $4 million from IEEPA tariff refunds.
Free cash flow was $54 million versus $28 million a year earlier; Building Performance Solutions adjusted EBITDA was flat at $60 million.
The Compensation Committee approved 150,000 performance shares for CEO Joseph Hayek on September 21, 2026; directors Michael J. Endres, Ozey K. Horton, Jr. and Virgil L. Winland retired at the annual meeting.
Nektar Therapeutics disclosed that a federal jury found Eli Lilly breached the implied covenant of good faith and fair dealing in their license agreement for rezpegaldesleukin. The jury awarded Nektar $90 million in damages plus interest, to be determined by the court. The verdict remains subject to post-trial proceedings and possible appeal, so the amount Nektar ultimately receives is not yet certain.
Jury verdict returned September 24, 2026 in Nektar Therapeutics v. Eli Lilly & Co., Case No. 3:23-cv-03943-JD
Jury awarded Nektar $90 million in damages plus interest, with interest to be set by the District Court
Verdict is subject to post-trial proceedings and any resulting judgment may be appealed
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.